Natera, Inc. (NASDAQ:NTRA) Stock Position Lessened by American Trust

American Trust reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 6.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,003 shares of the medical research company’s stock after selling 205 shares during the quarter. American Trust’s holdings in Natera were worth $381,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of NTRA. Covestor Ltd increased its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC boosted its stake in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares in the last quarter. CIBC Asset Management Inc grew its holdings in Natera by 3.3% during the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after acquiring an additional 111 shares during the period. RiverPark Advisors LLC raised its position in Natera by 3.5% in the third quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after acquiring an additional 112 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its holdings in Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after acquiring an additional 135 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $166.55 on Friday. Natera, Inc. has a fifty-two week low of $57.22 and a fifty-two week high of $175.63. The stock’s 50-day moving average is $144.02 and its two-hundred day moving average is $124.46. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a market cap of $21.99 billion, a P/E ratio of -94.63 and a beta of 1.63.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the previous year, the firm posted ($0.95) earnings per share. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on NTRA. Sanford C. Bernstein lifted their price objective on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. The Goldman Sachs Group lifted their target price on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Finally, Robert W. Baird upped their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $147.50.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now directly owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This trade represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Rowan E. Chapman sold 1,767 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total value of $300,814.08. Following the transaction, the director now directly owns 6,202 shares of the company’s stock, valued at $1,055,828.48. This represents a 22.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 137,987 shares of company stock valued at $21,895,591 over the last three months. 7.60% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.